Biogen’s stock slides premarket as analysts take mixed view of Alzheimer’s disease drug approval

Argentina Noticias Noticias

Biogen’s stock slides premarket as analysts take mixed view of Alzheimer’s disease drug approval
Argentina Últimas Noticias,Argentina Titulares
  • 📰 MarketWatch
  • ⏱ Reading Time:
  • 43 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 97%

Biogen Inc.’s stock rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval...

Biogen Inc.’s stock BIIB rose about 2% before paring those gains premarket Friday, after the U.S. Food and Drug Administration on Thursday granted full approval to Leqembi, the company’s Alzheimer’s disease treatment co-developed with Eisai Co. Ltd.

The step secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms. The drug’s label will have a boxed warning about amyloid-related imaging abnormalities, or ARIA, which usually have no symptoms but in some rare cases cause life-threatening brain swelling, the FDA said Thursday. Oppenheimer reiterated... Biogen Inc.’s stock BIIB rose about 2% before paring those gains premarket Friday, after the U.S.

The step secures Medicare reimbursement for the first drug shown to slow the progress of the disease, rather than just treating its symptoms. The drug’s label will have a boxed warning about amyloid-related imaging abnormalities, or ARIA, which usually have no symptoms but in some rare cases cause life-threatening brain swelling, the FDA said Thursday.

Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:

MarketWatch /  🏆 3. in US

Argentina Últimas Noticias, Argentina Titulares

Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.

US FDA grants standard approval of Eisai/Biogen Alzheimer's drugUS FDA grants standard approval of Eisai/Biogen Alzheimer's drugA new milestone for a fatal disease that has eluded drugmakers' efforts for decades.
Leer más »

July gallery roundup: The Gallery/Art Placement Inc.July gallery roundup: The Gallery/Art Placement Inc.Student exhibition I am Here, I am Human is on view at The Gallery/Art Placement Inc. until Aug. 4.
Leer más »

Cathie Wood’s ARK ETFs sold more Tesla stock, while buying Meta sharesCathie Wood’s ARK ETFs sold more Tesla stock, while buying Meta sharesCathie Wood’s ARK Investment exchange-traded funds sold more Tesla Inc. stock on Wednesday, while buying some Meta Platforms Inc. shares The ARK Next...
Leer más »

Bed Bath & Beyond investors have spent $200 million trading 'worthless' shares — will this holding company help them?Bed Bath & Beyond investors have spent $200 million trading 'worthless' shares — will this holding company help them?Bed Bath & Beyond investors have spent $200 million trading ‘worthless’ shares — will this holding company help them?
Leer más »

Meta’s stock pops 1.8% premarket as KeyBanc raises price target and backs overweight ratingMeta’s stock pops 1.8% premarket as KeyBanc raises price target and backs overweight ratingMeta Platforms Inc.’s stock rose 1.8% in premarket trade Thursday, after KeyBanc raised its stock price target on the Facebook parent to $335 from $280 and...
Leer más »

Uber, DoorDash sue New York City over minimum wage lawUber, DoorDash sue New York City over minimum wage lawUber Technologies Inc , DoorDash Inc and other app-based food delivery companies filed lawsuits on Thursday seeking to strike down New York City's novel law setting a minimum wage for delivery workers.
Leer más »



Render Time: 2025-04-03 17:32:25